How Dogan was paid
$1.3M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Other | Total |
|---|---|---|---|---|
| Meeshanthini V. DoganCEO | $300,000 | $1,004,656 | $11,000 | $1,315,656 |
| Warren HosseinionChairman | $300,000 | $75,349 | $0 | $375,349 |
| Elisa LuqmanCFO | $275,000 | $75,349 | $0 | $350,349 |
| Timur DoganCTO | $250,000 | $502,328 | $9,167 | $761,495 |
What changed and why
- $1.3M$1,315,656 was CEO total compensation in 2024, including $1,004,656 in stock option awards.
- $649K$648,893 was CEO total compensation in 2023, versus $1,315,656 in 2024.
- $0$0 was awarded in annual bonuses to named executive officers in both 2023 and 2024.
- $502K$502,328 was Timur Dogan’s 2024 stock option award value, while the CEO received $1,004,656.
- $11,000$11,000 and $9,167 were disclosed all-other compensation for Meeshanthini Dogan and Timur Dogan, respectively.
- $63.302024 option awards reflected discretionary grants valued using the Nasdaq adjusted closing stock price of $63.30.
Other Cardio Diagnostics Holdings proxy statements
- 2026 proxy statement
Meeshanthini V. Dogan paid $312,300 (-76% on the year).
Filed Aug 05, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.